New research from Spherix’s Launch Dynamix™ service captures neurologists’ current perceptions and reported prescribing behavior for the first-to-market disease-modifying therapy...
Spherix Global Insights data show Nurtec ODT expanding its dominance of the CGRP class for migraine prevention with little anticipated...
In addition to a thorough evaluation of the current diagnosis and management of celiac disease (CeD), five pipeline product profiles...
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat,...
One month post launch, Spherix data indicates that Aduhelm (aducanumab-avwa) awareness easily outpaces other key performance indicators, including degree of...
Spherix finds that perceptions related to efficacy appear to be impacting the new, more convenient formulation of the α4β7 integrin...
After several months on the market to treat lupus nephritis, uptake and prescribing patterns of Benlysta and Lupkynis reveal nephrologists...
Neurologists in Canada are receptive to having a fourth S1P receptor modulator option in Janssen’s Ponvory, although increasing the clinical...
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards...
New research from Spherix Global Insights finds the impressive uptake of AbbVie’s Ubrelvy and Biohaven’s Nurtec ODT appears to have...
Aside from an in-depth evaluation of the current diagnosis and management of NAFLD/NASH, ten pipeline product profiles were evaluated by...
US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different...
